Bsf Enterprise. Regulatory News (BSFA)

FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES IN ANY JURISDICTION.

26 September 2023

BSF Enterprise plc

("BSF" or the "Company")

Results of General Meeting

Allotment of shares‎‎ 

BSF Enterprise plc (LSE: BSFA), the Main Market listed biotech company and owner of pioneering UK-based clinical and cellular agriculture company 3D Bio-Tissues, is pleased to announce that at the Company's General Meeting held earlier today, all resolutions proposed were duly passed by shareholders by way of a poll.

Full details of the voting at the General Meeting are set out in the table below.

Allotment of Shares

As previously announced on 29 March and 12 April 2023, the Company confirms that it has today allotted 364,739 ordinary shares, constituting the 264,739 Second Tranche Shares and the 100,000 Financial PR Shares (together, "New Ordinary Shares"), conditionally on the admission of such New Ordinary Shares ‎to the Official List by way of a Standard Listing ‎and to trading on the London Stock Exchange's ‎Main Market for listed securities‎ ("Admission") at the issue price of 17 pence per New Ordinary Share, 7.25p or 43% above the share price as at 14:00 on 26 September 2023.

Applications have been made to the FCA and to the London Stock Exchange for the admission of the New Ordinary Shares ‎to the Official List by way of a Standard Listing ‎and to trading on the London Stock Exchange's ‎Main Market for listed securities. It is expected that Admission will become effective at or around 8.00 a.m. on 27 September 2023 and that dealings in the New Ordinary Shares will commence at that time and that trading in the New Ordinary Shares will resume at that time.

The New Ordinary Shares will, when issued, be credited as fully paid and will rank pari passu in all respects with the existing ordinary Shares of the Company and will on issue be free of all claims, liens, charges, encumbrances and equities.

Total Voting Rights

The Company confirms that with effect from Admission, the Company's issued share capital will comprise ‎103,336,937‎ ordinary shares of £0.01 each, with each share carrying the right to one vote. The Company does not hold any ordinary shares in treasury.

The above figure of ‎103,336,937 ‎ may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or of a change to their interest in the Company under the FCA's Disclosure and Transparency Rules.

Results of General Meeting

The resolutions were put to shareholders via a poll, the results of which were as follows:

The total number of ordinary shares in issue on 26 September 2023 was ‎102,972,198 shares.

The full text of the resolutions can be found in the Circular and Notice of General Meeting dated 7 September 2023, which is ‎available on the Company's website at:‎ https://www.bsfenterprise.com/investors

In accordance with the UK Listing Authority's Listing Rule 9.6.2, copies of all the ‎resolutions passed by the Company's shareholders, other than ordinary business will be ‎submitted to the National Storage Mechanism and will shortly be available for ‎inspection at

https://data.fca.org.uk/#/nsm/nationalstoragemechanism

Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as defined in the Circular.

Further announcements will be made in due course, as appropriate.

Enquiries:

For further information, please visit www.bsfenterprise.com.

LEI: ‎‎2138007PJT69H8FYLC06‎